Treatment of IBD: Where we are and where we are going

American Journal of Gastroenterology

Volumn 110, Issue 1, 2015, Pages 114-126

  Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CODEINE; COLESTYRAMINE; CORTICOSTEROID; DIPHENOXYLATE; IMMUNOMODULATING AGENT; JANUS KINASE INHIBITOR; LOPERAMIDE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; OPIATE; PARACETAMOL; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; VEDOLIZUMAB; IMMUNOLOGIC FACTOR;

ALTERNATIVE MEDICINE; CONFERENCE PAPER; DIARRHEA; ENTERIC FEEDING; FECAL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; MICROBIOME; TRANSPLANTATION; DRUG EFFECTS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES;

ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES;

EID: 84920675807     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.357     Document Type: Conference Paper

References (93)

1. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10: CD000543.
2. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10: CD000544.
3. Marshall JK, Thabane M, Steinhart AH et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;CD004115.
4. Marshall JK, Thabane M, Steinhart AH et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;11: CD004118.
5. Lichtenstein GR, Ramsey D, Rubin DT. Randomised clinical trial: delayedrelease oral mesalazine 4.8 g/day vs.2.4 g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Aliment Pharmacol Ther 2011;33: 672-8.
6. Feagan BG, Chande N, MacDonald JK. Are there any diff erences in the effi cacy and safety of diff erent formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis Evidence from Cochrane reviews. Infl amm Bowel Dis 2013;19: 2031-40.
7. Singleton JW, Hanauer SB, Gitnick GL et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 1993;104: 1293-301.
8. Ford AC, Bernstein CN, Khan KJ et al. Glucocorticosteroid therapy in infl ammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011, 106, 590-9
9. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63: 433-41.
10. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143: 1218-26.
11. Toruner M, Loftus EV Jr, Harmsen WS et al. Risk factors for opportunistic infections in patients with infl ammatory bowel disease. Gastroenterology 2008;134: 929-36.
12. Ferrante M, D'Hoore A, Vermeire S et al. Corticosteroids but not infl iximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Infl amm Bowel Dis 2009;15: 1062-70.
13. Targownik LE, Nugent Z, Singh H et al. Prevalence of and outcomes associated with corticosteroid prescription in infl ammatory bowel disease. Infl amm Bowel Dis 2014;20: 622-30.
14. Khan KJ, Dubinsky MC, Ford AC et al. Effi cacy of immunosuppressive therapy for infl ammatory bowel disease: a systematic review and metaanalysis. Am J Gastroenterol 2011;106: 630-42.
15. Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013;145: 758-65.
16. Pan J, Lez-San Rom A, Bermejo F. et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145: 766-74.
17. Rogler G, Sandborn W. Is there still a role for thiopurines in Crohn's disease Gastroenterology 2013;145: 714-6.
18. Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyltransferase enzyme testing in infl ammatory bowel disease. Can J Gastroenterol. 2013;27: 39-43.
19. Present DH, Korelitz BI, Wisch N. et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302: 981-7.
20. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profi les provide a biochemical explanation for 6-MP resistance in patients with infl ammatory bowel disease. Gastroenterology 2002;122: 904-15.
21. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with infl ammatory bowel disease. Am J Gastroenterol. 2004;99: 1744-8.
22. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995;332: 292-7.
23. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000;342: 1627-32.
24. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330: 1841-5.
25. Ogata H, Kato J, Hirai F et al. A randomized dose fi nding study of oral tacrolimus (FK506) therapy in the management of hospitalized patients with refractory ulcerative colitis. Infl am Bowel Dis 2012;18: 803-8.
26. Ogata H, Matsui T, Nakamura M et al. A randomised dose fi nding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006;55: 1255-62.
27. Jnerot G, Hertervig E, Friis-Liby I et al. Infl iximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128: 1805-11.
28. Laharie D, Bourreille A, Branche J et al. Ciclosporin versus infl iximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380: 1909-15.
29. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Effi cacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebocontrolled trials. Clin Gastroenterol Hepatol 2008;6: 644-53.
30. Danese S, Fiorino G, Peyrin-Biroulet L. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network metaanalysis. Ann Intern Med 2014;160: 704-11.
31. Colombel JF, Sandborn WJ, Reinisch W. et al. Infl iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
32. Panaccione R, Ghosh S, Middleton S et al. Combination therapy with infl iximab and azathioprine is superior to monotherapy wiTheither agent in ulcerative colitis. Gastroenterology 2014;146: 392-400
33. Feagan BG, McDonald JW, Panaccione R et al. Methotrexate in combination with infl iximab is no more effective than infl iximab alone in patients with Crohn's disease. Gastroenterology 2014;146: 681-8.
34. Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013;108: 1835-42.
35. Roblin X, Rinaudo M, Del Tedesco E et al. Development of an algorithm incorporating pharmacokinetics of adalimumab in infl ammatory bowel diseases. Am J Gastroenterol 2014;109: 1250-6.
36. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infl iximab: a randomized trial. Ann Intern Med 2007;146: 829-38.
37. Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy aft er infl iximab therapy is stopped. Gastroenterology 2012;142: 63-70.
38. Molander P, FkkilM, Salminen K et al. Outcome aft er discontinuation of TNFalpha;-blocking therapy in patients with infl ammatory bowel disease in deep remission. Infl amm Bowel Dis 2014;20: 1021-8.
39. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369: 699-710.
40. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369: 711-21.
41. Sands BE, Feagan BG, Rutgeerts P et al. Eff ects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment had failed. Gastroenterology 2014;147: 618-627.e3.
42. Vermeire S, O'Byrne S, Keir M et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384: 309-18.
43. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367: 1519-28.
44. Kopylov U, Afif W, Cohen A et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience. J Crohns Colitis 2014;pii: S1873-9946 (e-pub ahead of print).
45. Sandborn WJ, Ghosh S, Panes J et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367: 616-24.
46. Khan KJ, Ullman TA, Ford AC et al. Antibiotic therapy in infl ammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106: 661-73.
47. Rutgeerts P, Hiele M, Geboes K et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence aft er ileal resection. Gastroenterology 1995;108: 1617-21.
48. Rutgeerts P, Van Assche G, Vermeire S et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128: 856-61.
49. D'Haens GR, Vermeire S, Van Assche G et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a randomized controlled trial. Gastroenterology 2008;135: 1123-9.
50. Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of infl ammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 2012;72: 803-23.
51. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebocontrolled trial. Lancet 2008;371: 651-9.
52. Gibson GR, Probert HM, Van Loo J et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. Nutr Res Rev 2004;17: 259-75.
53. Benjamin JL, Hedin CRH, Koutsoumpas A et al. Randomized, doubleblind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011;60: 923-9.
54. De Preter V, Joossens M, Ballet V et al. Metabolic profi ling of the impact of oligofructose-enriched inulin in Crohn's disease patients: a double-blind randomized controlled trial. Clin Transl Gastroenterol 2013;4: e30.
55. Critch J, Day AS, Otley A et al. Use of enteral nutrition for the control of intestinal infl ammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012;54: 298-305.
56. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol 2013;19: 7652-60.
57. Levine A, Wine E. Eff ects of enteral nutrition on Crohn's disease: clues to the impact of diet on disease pathogenesis. Infl amm Bowel Dis 2013;19: 1322-9.
58. Bernstein KI, Promislow S, Carr R et al. Information needs and preferences of recently diagnosed patients with infl ammatory bowel disease. Infl amm Bowel Dis 2011;17: 590-8.
59. Hou JK, Lee D, Lewis J. Diet and infl ammatory bowel disease: review of patient-targeted recommendations. Clin Gastroenterol Hepatol 2014;12: 1592-600.
60. Claesson MJ, Jeffery IB, Conde S et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488: 178-84.
61. Smits LP, Bouter KE, de Vos WM et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013;145: 946-53.
62. Kump PK, Grhenig HP, Lackner S et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Infl amm Bowel Dis 2013;19: 2155-65.
63. Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients aft er fecal microbiota transplantation. Am J Gastroenterol 2013;108: 1620-30.
64. Rubin DT. Curbing our enthusiasm for fecal transplantation in ulcerative colitis. Am J Gastroenterol 2013;108: 1631-3.
65. Moayyedi P, Surette P, Wolfe M et al. A randomized, placebo controlled trial of fecal microbiota therapy in active ulcerative colitis. Gastroenterology 2014;146 (Supplement 1): S-159.
66. Rawsthorne P, Clara I, Graff LA et al. The Manitoba Infl ammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products. Gut 2012;61: 521-7.
67. Abitbol V, Lahmek P, Buisson A et al. Impact of complementary and alternative medicine on the quality of life in infl ammatory bowel disease: results from a French national survey. J Gastroenterol Hepatol 2014;26: 288-94.
68. Koning M, Ailabouni R, Gearry RB et al. Use and predictors of oral complementary and alternative medicine by patients with infl ammatory bowel disease: a population-based, case-control study. Infl amm Bowel Dis 2013;19: 767-78.
69. Opheim R, Bernklev T, Fagermoen MS et al. Use of complementary and alternative medicine in patients with infl ammatory bowel disease: results of a cross-sectional study in Norway. Scand J Gastroenterol 2012;47: 1436-47.
70. Salstrok;aga M, Zatorski H, Sobczak M et al. Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review. Curr Treat Options Oncol 2014;15: 405-20.
71. Ji J, Lu Y, Liu H et al. Acupuncture and moxibustion for infl ammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013;2013: 158352.
72. Ng SC, Lam YT, Tsoi KK et al. Systematic review: the effi cacy of herbal therapy in infl ammatory bowel disease. Aliment Pharmacol Ther 2013;38: 854-63.
73. Singh S, Blanchard A, Walker JR et al. Common symptoms and stressors among individuals with infl ammatory bowel diseases. Clin Gastroenterol Hepatol 2011;9: 769-75.
74. Bernstein CN, Singh S, Graff LA et al. A prospective population-based study of symptomatic triggers of fl ares in IBD. Am J Gastroenterol 2010;105: 1994-2002.
75. Targownik LE, Sexton K, Bernstein MT et al. The eff ect of psychological distress and perceived stress on change in symptom activity and infl ammation over time in Crohn's disease. Gastroenterology. 2014;146: S-234.
76. Singh S, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections or stress trigger fl ares in IBD Am J Gastroenterol 2009;104: 1298-313.
77. Targownik LE, Nugent Z, Singh H et al. The prevalence and predictors of opioid use in infl ammatory bowel disease: a population based analysis. Am J Gastroenterol 2014;109: 1613-20.
78. Hanson KA, Loftus EV Jr, Harmsen WS et al. Clinical features and outcome of patients with infl ammatory bowel disease who use narcotics: a casecontrol study. Infl amm Bowel Dis 2009;15: 772-7.
79. Long MD, Barnes EL, Herfarth HH et al. Narcotic use for infl ammatory bowel disease and risk factors during hospitalization. Infl amm Bowel Dis 2012;18: 869-76.
80. Storr M, Devlin S, Kaplan GG et al. Cannabis use provides symptom relief in patients with infl ammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Infl amm Bowel Dis 2014;20: 472-80.
81. Lal S, Prasad N, Ryan M et al. Cannabis use amongst patients with infl ammatory bowel disease. Eur J Gastroenterol Hepatol 2011;23: 891-6.
82. Naftali T, Bar-Lev Schleider L, Dotan I et al. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol 2013;11: 1276-80.
83. van Outryve M, Toussaint J. Loperamide oxide for the treatment of chronic diarrhoea in Crohn's disease. J Int Med Res 1995;23: 335-41.
84. Mainguet P, Fiasse R. Double-blind placebo-controlled study of loperamide (Imodium) in chronic diarrhoea caused by ileocolic disease or resection. Gut 1977;18: 575-9.
85. Hallgren T, Fasth S, Delbro DS et al. Loperamide improves anal sphincter function and continence aft er restorative proctocolectomy. Dig Dis Sci 1994;39: 2612-8.
86. Engbaek J, Ersbl J, Faurby V et al. The constipating eff ect of diphenoxylate (Retardinr) in ulcerative colitis. A double-blind controlled trial. Scand J Gastroenterol 1975;10: 695-8.
87. Bergman L, Djv L. A comparative study of loperamide and diphenoxylate in the treatment of chronic diarrhoea caused by intestinal resection. Ann Clin Res 1981;13: 402-5.
88. Jacobsen O, Hgaard L, Hylander Mler E et al. Eff ect of enterocoated cholestyramine on bowel habit aft er ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 1985;290: 1315-8.
89. Ilnyckyj A, Shanahan F, Anton PA et al. Quantifi cation of the placebo response in ulcerative colitis. Gastroenterology 1997;112: 1854-8.
90. Su C, Lichtenstein GR, Krok K et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126: 1257-69.
91. Su C, Lewis JD, Goldberg B et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007;132: 516-26.
92. Bernstein CN. The placebo eff ect for gastroenterology: Tool or torment. Clin Gastroenterol Hepatol 2006;4: 1302-8.
93. Melesse DY, Targownik LE, Blanchard JF et al. Patterns of IBD-specifi c Medications Nonuse in Persons with Infl ammatory Bowel Diseases: a population-based study. Gastroenterology 2013;144: S48-S49.